Newsroom

01/27/2016 2016 PHARMA LEADER TGV-LABORATORIES DEVELOPS BREAKTHROUGH DRUG TO FIGHT ‘ANTIBIOTIC APOCALYPSE’

New York, NY – January 27, 2016 –A New York pharmaceutical company, TGV-Laboratories, has developed a groundbreaking drug that shows promise in treating a wide variety of antibiotic-resistant fungal and bacterial infections.

Read More

12/08/2015 TGV-INHALONIX FILES FOR ORPHAN DRUG STATUS FOR NEW CLASS OF ANTIBIOTIC TO TREAT RESISTANT INFECTIONS IN CYSTIC FIBROSIS

New York, NY – December 8, 2015 – TGV-Inhalonix, Inc., a New York-based pharmaceutical company, recently announced that it has submitted an application for Orphan Drug Designation to the U.S. Food and Drug Administration (FDA) for its novel antibiotic Mul-1867, which shows promise in treating drug-resistant bacterial pulmonary infections in patients with cystic fibrosis…

Read More

11/06/2015 ARTICLE PUBLISHED IN ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL
“IN VITRO ANTIMICROBIAL ACTIVITY OF A NOVEL COMPOUND, MUL-1867, AGAINST CLINICALLY IMPORTANT BACTERIA”

Read More

09/21/2015 POSTER FROM ICAAC 2015 MEETING, SEPTEMBER 17 – 21, 2015 IN SAN DIEGO, CALIFORNIA.
TETZ, G., TETZ V.

POSTER.PDF

09/21/2015 ABSTRACT FROM ICAAC 2015 MEETING, SEPTEMBER 17 – 21, 2015 IN SAN DIEGO, CALIFORNIA.
TETZ, G., TETZ V.

Study of Mul-1867 a drug candidate for inhalation therapy of pulmonary exacerbations caused by Burkholderia cepacia in patients with cystic fibrosis and COPD patients

Read More

07/02/2015 POSTER FROM ASM 2015 MEETING, NEW ORLEANS, MAY 30 – JUNE 02, 2015
TETZ, G., TETZ V.

POSTER.PDF

05/30/2015 ABSTRACT FROM ASM 2015 MEETING, NEW ORLEANS, MAY 30 – JUNE 02, 2015
TETZ, G., TETZ V.

Nanoglobular and linear antimicrobials against biofilms formed by Burkholderia cepacia isolated from cystic fibrosis patients.
Read More

10/06/2015 TGV-THERAPEUTICS’ MUL-1867 FOR CYSTIC FIBROSIS AND COPD PATIENTS INFECTED WITH BURKHOLDERIA CEPACIA ACHIEVES POSITIVE RESULTS IN PILOT STUDY

New York, NY, June 10, 2015.  TGV-Therapeutics announcedpositive results from the  first-in-human pilot study of Mul-1867 in 10 cystic fibrosis and COPD patients infected with Burkholderia cepacia. Short-term administration of inhaled 0.25% Mul-1867 during pulmonary exacerbation improves pulmonary function, decreases the density of B.cepacia in expectorated sputum. All patients showed clinical improvement and resolution of their acute respiratory exacerbation. The clinical assessments at day 7, 14 and 28 demonstrated a significant difference in outcome and improvement of symptoms between pretreatment period.

02/10/2015 TGV-THERAPEUTICS INITIATES PILOT STUDY OF MUL-1867 IN CYSTIC FIBROSIS PATIENTS INFECTED WITH BURKHOLDERIA CEPACIA

New York, NY, February 10, 2015.  TGV-Therapeutics today announced the initiation of a  pilot-study of Mul-1867 in cystic fibrosis patients infected with Burkholderia cepacia.  The study will…

Read More

10/23/2014 TGV-THERAPEUTICS HONORED TO ATTEND PRIX GALIEN AWARD CEREMONY

New York, NY, October 23, 2014. TGV-Therapeutics announces that it was selected by the Prix Galien Jury as the most exciting and promising project. As the selected laureate, representatives from TGV-Therapeutics have taken part of the Prix Galien award ceremony…

Read More

11/01/2014 TGV-THERAPEUTICS’ MUL-1867-CF FOR CYSTIC FIBROSIS PATIENTS ACHIEVES POSITIVE RESULTS IN PILOT STUDY

New York, NY, November 01, 2014. TGV-Therapeutics announces positive results from the  first-in-human pilot study of Mul-1867-CF in 15 cystic fibrosis patients during pulmonary exacerbation….

Read More